Guggenheim Assumes TherapeuticsMD (TXMD) at Buy Ahead of Positive Expected TX-001HR Data

November 7, 2016 6:13 AM EST
Get Alerts TXMD Hot Sheet
Price: $5.74 --0%

Rating Summary:
    9 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 9 | Down: 12 | New: 44
Trade TXMD Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Guggenheim assumes coverage on TherapeuticsMD (NYSE: TXMD) with a Buy rating and a price target of $33.00, saying they see positive data for TX-001HR in 4Q16.

Analyst Louise Chen commented, "We are assuming coverage of TXMD. It is a good time to take a look at TXMD ahead of what we believe will be positive data for TX-001HR in 4Q16. We also expect TXMD to receive approval for Yuvvexy on its PDUFA date of 5/7/17. We believe these two drugs have blockbuster potential that are underappreciated by the Street. Yuvvexy for VVA would have earlier onset of action, lower systemic exposure, and greater ease of use than other therapies on the market. TX-001HR for hot flashes has potential to be the first FDA-approved bio-identical hormone therapy containing natural estradiol and progesterone. These drugs target a multibillion-dollar market opportunity."

For an analyst ratings summary and ratings history on TherapeuticsMD click here. For more ratings news on TherapeuticsMD click here.

Shares of TherapeuticsMD closed at $5.12 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA, Hot New Coverage, New Coverage

Related Entities

Louise Chen, PDUFA, Guggenheim

Add Your Comment